52558-24-4

Basic information

• Product Name: Propanoic acid, 3-[[(1,1-dimethylethoxy)carbonyl]amino]-2-hydroxy-, (2S)-
• Synonyms: Propanoic acid, 3-[[(1,1-dimethylethoxy)carbonyl]amino]-2-hydroxy-, (2S)-;(S)-3-(tert-Butyloxycarbonylamino)-2-hydroxypropionic acid;(2S)-3-[[(1,1-Dimethylethoxy)carbonyl]amino]-2-hydroxy-propanoic acid;3-tert-ButoxycarbonylaMino-(S)-2-hydroxy-propionic acid;Boc-(S)-isoserine;(S)-3-(Boc-aMino)-2-hydroxy-propanoic acid;(S)-3-((tert-Butoxycarbonyl)aMino)-2-hydroxypropanoic acid
• CAS NO: 52558-24-4
• Molecular Formula: C₈H₁₅NO₅
• Molecular Weight: 205.2084
• Product Categories: N-BOC
• Mol File: 52558-24-4.mol
• Article Data: 16

Chemical Properties

• Boiling Point: 391.7 °C at 760 mmHg
• Flash Point: 190.7 °C
• Appearance: /
• Density: 1.24 g/cm³
• Storage Temp.: 2-8°C
• PKA: 3.58±0.11(Predicted)
• CAS DataBase Reference: Propanoic acid, 3-[[(1,1-dimethylethoxy)carbonyl]amino]-2-hydroxy-, (2S)-(CAS DataBase Reference)
• NIST Chemistry Reference: Propanoic acid, 3-[[(1,1-dimethylethoxy)carbonyl]amino]-2-hydroxy-, (2S)-(52558-24-4)
• EPA Substance Registry System: Propanoic acid, 3-[[(1,1-dimethylethoxy)carbonyl]amino]-2-hydroxy-, (2S)-(52558-24-4)

Safety Data

• Hazardous Substances Data: 52558-24-4(Hazardous Substances Data)

Usage

General Description

Propanoic acid, 3-[[(1,1-dimethylethoxy)carbonyl]amino]-2-hydroxy- (2S)- is a chemical compound that is also known as Tenofovir alafenamide, a prodrug of tenofovir. It is used as an antiretroviral medication for the treatment of HIV-1 infection and chronic hepatitis B virus. Tenofovir alafenamide is designed to be more efficiently delivered to target cells, allowing for lower doses and reducing the potential for kidney and bone toxicity compared to its predecessor, tenofovir disoproxil. It is a white to off-white crystalline powder that is highly soluble in water, and its chemical structure is composed of propanoic acid, amino groups, and hydroxy groups.

Upstream product

• 565-71-9 L-isoserine 
• 24424-99-5 di-tert-butyl dicarbonate 
• 56-40-6 glycine 
• 169688-48-6 benzyl-(S)-N-tert-butoxycarbonyl-2-oxo-5-oxazolidine carboxylate 

Downstream Products

• 1335122-95-6 C₂₂H₃₄N₄O₉ 
• 1355251-82-9 1,4:3,6-dianhydro-5-O-(benzyl)-2-N-(N-t-butoxycarbonyl-L-isoserine)-D-glucitol 
• 1346507-67-2 tert-butyl (2R,3R,6S)-2-((1R,2S,3S,4R,6S)-3-((2R,3R,4R,5R)-3,5-dihydroxy-5-methyl-4-(N-methyl-tert-butoxycarbonylamino)tetrahydro-2H-pyran-2-yloxy)-2-hydroxy-4-((S)-2-hydroxy-3-tert-butoxycarbonylaminopropanamido)-6-tert-butoxycarbonylaminocyclohexyloxy)-6-((2-nitrophenylsulfonamido)methyl)tetrahydro-2H-pyran-3-ylcarbamate 
• 1287277-05-7 C₇₄H₈₃N₇O₂₃ 
• 1154759-14-4 6'-(N-boc-3-amino-2-hydroxy-propionyl)-2',3-diPNZ-1-(N-boc-3-amino-2(S)-hydroxy-propionyl)-3-boc-sisomicin 
• 1154758-60-7 6'-PNZ-2',3,3''-triBoc-1-(N-Boc-3-amino-2(S)-hydroxy-propionyl)-sisomicin 
• 458531-95-8 N^α-[3-(tert-butyloxycarbonyl)-2(R)-(acetylsulfanyl)propionyl]-leucyl-O-methyl-tyrosine N-methylamide 
• 458531-93-6 N^α-[3-(tert-butyloxycarbonyl)-2(S)-hydroxypropionyl]-leucyl-O-methyl-tyrosine N-methylamide 
• 1154758-61-8 2',3,3''-triBoc-1-(N-Boc-3-amino-2(S)-hydroxy-propionyl)-sisomicin 
• 1154758-46-9 6'-trifluoroacetyl-2',3-diPNZ-1-(N-Boc-3-amino-2(S)-hydroxy-propionyl)-3''-Boc-sisomicin 
• 1154758-43-6 6'-trifluoroacetyl-2',3-diPNZ-1-((R)-3-(tert-butoxycarbonylamino)-2-hydroxy-propionyl)-3''-Boc-sisomicin 
• 1154758-85-6 6'-(methyl-cyclopropyl)-2',3-diPNZ-1-(N-Boc-3-amino-2(R)-hydroxy-propionyl)-3''-Boc-sisomicin 
• 1154758-45-8 6'-trifluoroacetyl-2',3-diPNZ-1-(N-Boc-3-amino-2(S)-hydroxy-propionyl)-sisomicin 
• 1154758-42-5 6'-trifluoroacetyl-2',3-diPNZ-1-((R)-3-(tert-butoxycarbonylamino)-2-hydroxy-propionyl)-sisomicin 

Relevant articles and documents

?-LACTAMASE INHIBITOR AND USE THEREOF

Provided are a β-lactamase inhibitor of formula (I), or an ester, a stereoisomer or a pharmaceutically acceptable salt thereof, and a method of preparing the same. Further provided is a pharmaceutical composition comprising the β-lactamase inhibitor of formula (I), or the ester, the stereoisomer or pharmaceutically acceptable salt thereof. In addition, the present invention relates to a method for treating diseases caused by bacterial infection, which comprises administering the β-lactamase inhibitor of formula (I), or the ester, the stereoisomer or the pharmaceutically acceptable salt thereof to a patient or a subject in need.

Amine compound for inhibiting SSAO/VAP-1 and application thereof in medicines

The present invention relates to an amine compound for inhibiting SSAO/VAP-1 and application thereof in medicines. In particular, the present invention relates to an amine compound for inhibiting a semicarbazide-sensitive oxidase (SSAO) and/or vascular adhesion protein-1 (VAP-1) inhibitor, or a pharmaceutically acceptable salt thereof, a stereoisomer or an/a E/Z isomer, further relates to a pharmaceutical composition containing the amine compound. The invention further relates to the application of the amine compound and the pharmaceutical composition in manufacture of the medicines for treatment of inflammation, inflammation-related diseases and immune diseases.

Design, synthesis and biological evaluation of novel L-isoserine tripeptide derivatives as aminopeptidase N inhibitors

Aminopeptidase N (APN/CD13) is one of the essential proteins for tumour invasion, angiogenesis and metastasis as it is over-expressed on the surface of different tumour cells. Based on our previous work that L-isoserine dipeptide derivatives were potent APN inhibitors, we designed and synthesized L-isoserine tripeptide derivatives as APN inhibitors. Among these compounds, one compound 16l (IC50=2.51±0.2 M) showed similar inhibitory effect compared with control compound Bestatin (IC50=6.25±0.4 M) and it could be used as novel lead compound for the APN inhibitors development as anticancer agents in the future.